全文获取类型
收费全文 | 8023篇 |
免费 | 442篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 153篇 |
妇产科学 | 93篇 |
基础医学 | 1505篇 |
口腔科学 | 119篇 |
临床医学 | 679篇 |
内科学 | 1262篇 |
皮肤病学 | 179篇 |
神经病学 | 923篇 |
特种医学 | 297篇 |
外科学 | 1145篇 |
综合类 | 47篇 |
一般理论 | 2篇 |
预防医学 | 427篇 |
眼科学 | 247篇 |
药学 | 667篇 |
中国医学 | 12篇 |
肿瘤学 | 714篇 |
出版年
2022年 | 64篇 |
2021年 | 107篇 |
2020年 | 55篇 |
2019年 | 98篇 |
2018年 | 100篇 |
2017年 | 74篇 |
2016年 | 95篇 |
2015年 | 143篇 |
2014年 | 170篇 |
2013年 | 290篇 |
2012年 | 426篇 |
2011年 | 459篇 |
2010年 | 285篇 |
2009年 | 275篇 |
2008年 | 479篇 |
2007年 | 555篇 |
2006年 | 520篇 |
2005年 | 602篇 |
2004年 | 503篇 |
2003年 | 548篇 |
2002年 | 497篇 |
2001年 | 108篇 |
2000年 | 80篇 |
1999年 | 119篇 |
1998年 | 145篇 |
1997年 | 104篇 |
1996年 | 90篇 |
1995年 | 71篇 |
1994年 | 65篇 |
1993年 | 84篇 |
1992年 | 52篇 |
1991年 | 77篇 |
1990年 | 62篇 |
1989年 | 69篇 |
1988年 | 43篇 |
1987年 | 37篇 |
1986年 | 38篇 |
1985年 | 41篇 |
1984年 | 38篇 |
1983年 | 38篇 |
1982年 | 38篇 |
1981年 | 37篇 |
1980年 | 35篇 |
1979年 | 49篇 |
1978年 | 45篇 |
1977年 | 57篇 |
1975年 | 38篇 |
1974年 | 44篇 |
1973年 | 35篇 |
1972年 | 31篇 |
排序方式: 共有8522条查询结果,搜索用时 0 毫秒
131.
Zusammenfassung Das leicht abspaltbare Bluteisen (l. a. Eisen) nahm im Blute von Hunden nach Kohlenoxydvergiftung ab. Die Verminderung trat sofort mit der Aufnahme von Kohlenoxyd ein. Bei einem Kohlenoxydhämoglobingehalt von 40–50% des Gesamthämoglobins sank das l. a. Eisen auf etwa die Hälfte seiner ursprünglichen Konzentration. Mit der Ausscheidung des Kohlenoxyds stieg auch der Gehalt des Blutes an l. a. Eisen wieder an und hatte 24 Stunden nach Beendigung der Vergiftung wieder normale Werte erreicht, dabei war es gleichgültig, ob die Vergiftung durch einmalige oder wiederholte kurzdauernde Einatmung von reinem Kohlenoxyd oder lang dauernde Einatmung niedriger Kohlenoxydkonzentrationen erfolgte.Barkans Angaben, daß das l. a. Eisen noch lange Zeit nach einer Kohlenoxydvergiftung vermindert ist, ließen sich also nicht bestätigen. Damit entfällt eine wichtige Stütze für die Annahme, daß der mit Kohlenoxyd hemmbare Anteil des l. a. Eisen einer vom Hämoglobin verschiedenen Verbindung zukomme. Das abgespaltene Eisen lag zum größten Teil in zweiwertiger Form vor.Die photometrische Bestimmung des l. a. Eisen durch Bildung eines Phenanthrolin- oder Dipyridylkomplexes im Trichloressigsäurefiltrat wird durch unbekannte Faktoren gestört, die eine Zunahme der Extinktion über viele Stunden bedingen und einen zu hohen Eisengehalt vortäuschen. Durch Verbrennung des Filtrates konnte der Fehler ausgeschaltet werden.Mit 3 Textabbildungen. 相似文献
132.
Romi Goldschlager Hedley Roth Jarryd Solomon Scott Robson Jessica Green Sarah Green Manfred Spanger Robyn Gunn Peter Cameron 《Emergency radiology》2014,21(4):367-372
Current literature suggests that a large proportion of chest X-rays (CXRs) performed in emergency department (ED) patients with chest pain and suspected acute coronary syndrome (ACS) are unnecessary. The Canadian ACS Guidelines aim to guide clinicians in the appropriate use of CXR within this patient population. This study determined the prevalence of clinically significant CXR abnormalities and assessed the utility of the guidelines in a population of ED patients with chest pain and suspected ACS. Included in the study were participants over the age of 18 who presented to an Australian metropolitan ED, over a 1-year period, with a primary complaint of chest pain and who had a CXR and troponin level ordered in the ED (N?=?760). We retrospectively compared their radiographic findings with their recommendations for CXR according to the ACS Guidelines. We found that 12 % of the participants had a clinically significant chest X-ray. The guidelines had a sensitivity of 80 % (95 % CI 0.70–0.87) and specificity of 50 % (95 % CI 0.47–0.54). The positive predictive value was 18 % (95 % CI 0.15–0.22) with a 95 % negative predictive value (95 % CI 0.92–0.97). Had the ACS guidelines been applied to our patient population, the number of CXR performed would have been reduced by 47 %. This study suggests that the ACS Guidelines has the potential to reduce the numbers of unnecessary CXR performed in ED patients. However, this would come at the expense of missing a minority of significant CXR abnormalities. 相似文献
133.
134.
Lorena Rosik Günter Niegisch Ute Fischer Manfred Jung Wolfgang Arthur Schulz Michèle Janine Hoffmann 《Cancer biology & therapy》2014,15(6):742-757
Epigenetic modifiers such as histone deacetylases (HDACs) have come into focus as novel drug targets for cancer therapy due to their functional role in tumor progression. Since common pan-HDAC inhibitors have adverse side effects and minor anti-cancer activity against solid tumors, enzyme-specific inhibitors were developed. HDAC6 is especially well-suited for specific inhibition due to its unique domain structure and mode of action and has been suggested to provide an exceptionally suitable target for cancer therapy. However, expression and function of HDACs have been insufficiently studied in urothelial cancers (UC), a disease urgently requiring new therapeutic approaches. The present study sought to evaluate HDAC6 as a target for treatment of urothelial cancers with enzyme-specific inhibitors. We observed moderate HDAC6 overexpression in urothelial cancer tissues and a broad range of expression in urothelial cancer cell lines. In the cell lines Tubacin was the most potent inhibitor, compared with Tubastatin and ST-80, but still active only at high micromolar concentrations. HDAC6 expression levels correlated poorly with sensitivity to enzyme inhibition. Combined treatments with heat shock, HSP90 inhibition by 17-AAG, proteasome inhibition by bortezomib, or DNA-damaging agents did not result in significant synergistic effects. Experiments with siRNA-mediated knockdown further underlined that urothelial cancer cells do not critically depend on HDAC6 expression for survival. 相似文献
135.
136.
Biswa Nath Sharma Manfred Marschall Stian Henriksen Christine Hanssen Rinaldo 《Antimicrobial agents and chemotherapy》2014,58(1):279-289
Polyomavirus BK (BKV) causes polyomavirus-associated nephropathy (PyVAN) and hemorrhagic cystitis (PyVHC) in renal and bone marrow transplant patients, respectively. Antiviral drugs with targeted activity against BKV are lacking. Since the antimalarial drug artesunate was recently demonstrated to have antiviral activity, the possible effects of artesunate on BKV replication in human primary renal proximal tubular epithelial cells (RPTECs), the host cells in PyVAN, were explored. At 2 h postinfection (hpi), RPTECs were treated with artesunate at concentrations ranging from 0.3 to 80 μM. After one viral replication cycle (approximately 72 hpi), the loads of extracellular BKV DNA, reflecting viral progeny production, were reduced in a concentration-dependent manner. Artesunate at 10 μM reduced the extracellular BKV load by 65%; early large T antigen mRNA and protein expression by 30% and 75%, respectively; DNA replication by 73%; and late VP1 mRNA and protein expression by 47% and 64%, respectively. Importantly, the proliferation of RPTECs was also inhibited in a concentration-dependent manner. At 72 hpi, artesunate at 10 μM reduced cellular DNA replication by 68% and total metabolic activity by 47%. Cell impedance and lactate dehydrogenase measurements indicated a cytostatic but not a cytotoxic mechanism. Flow cytometry and 5-ethynyl-2′-deoxyuridine incorporation revealed a decreased number of cells in S phase and suggested cell cycle arrest in G0 or G2 phase. Both the antiproliferative and antiviral effects of artesunate at 10 μM were reversible. Thus, artesunate inhibits BKV replication in RPTECs in a concentration-dependent manner by inhibiting BKV gene expression and genome replication. The antiviral mechanism appears to be closely connected to cytostatic effects on the host cell, underscoring the dependence of BKV on host cell proliferative functions. 相似文献
137.
138.
Alessandro Bitto Chad A. Lerner Timothy Nacarelli Elizabeth Crowe Claudio Torres Christian Sell 《Age (Dordrecht, Netherlands)》2014,36(3):1123-1137
Advanced age is characterized by increased incidence of many chronic, noninfectious diseases that impair the quality of living of the elderly and pose a major burden on the healthcare systems of developed countries. These diseases are characterized by impaired or altered function at the tissue and cellular level, which is a hallmark of the aging process. Age-related impairments are likely due to loss of homeostasis at the cellular level, which leads to the accumulation of dysfunctional organelles and damaged macromolecules, such as proteins, lipids, and nucleic acids. Intriguingly, aging and age-related diseases can be delayed by modulating nutrient signaling pathways converging on the target of rapamycin (TOR) kinase, either by genetic or dietary intervention. TOR signaling influences aging through several potential mechanisms, such as autophagy, a degradation pathway that clears the dysfunctional organelles and damaged macromolecules that accumulate with aging. Autophagy substrates are targeted for degradation by associating with p62/SQSTM1, a multidomain protein that interacts with the autophagy machinery. p62/SQSTM1 is involved in several cellular processes, and its loss has been linked to accelerated aging and to age-related pathologies. In this review, we describe p62/SQSTM1, its role in autophagy and in signaling pathways, and its emerging role in aging and age-associated pathologies. Finally, we propose p62/SQSTM1 as a novel target for aging studies and age-extending interventions. 相似文献
139.
Inga Hoffmann Martin Roatsch Martin L. Schmitt Luca Carlino Martin Pippel Wolfgang Sippl Manfred Jung 《Molecular oncology》2012,6(6):683-703
Reversible histone methylation has emerged in the last few years as an important mechanism of epigenetic regulation. Histone methyltransferases and demethylases have been identified as contributing factors in the development of several diseases, especially cancer. Therefore, they have been postulated to be new drug targets with high therapeutic potential. Here, we review histone demethylases with a special focus on their potential role in oncology drug discovery. We present an overview over the different classes of enzymes, their biochemistry, selected data on their role in physiology and already available inhibitors. 相似文献
140.
Helge Hebestreit Annette Sauer-Heilborn Rainald Fischer Manfred Käding Jochen G. Mainz 《Journal of cystic fibrosis》2013,12(6):599-603
BackgroundRecently, ivacaftor, a CFTR-potentiator, has been shown to be effective and safe in patients with cystic fibrosis carrying a G551D mutation and moderately impaired lung function. The objective of this retrospective study was to assess efficacy and safety of ivacaftor in severely ill patients with at least one G551D mutation.MethodsData from 14 patients with a FEV1 < 40% predicted who received ivacaftor on a “named patient program” base in Germany were analyzed.ResultsOne patient took ivacaftor at a lower than recommended dose due to abundant mucus and a feeling to “suffocate.” No additional severe adverse events were reported. One further patient stopped ivacaftor due to lung transplantation, one due to perceived poor effectiveness, one due to pregnancy, and one stopped standard therapy. The remaining patients took ivacaftor regularly and did not change other therapies. FEV1 increased by more than 5 %predicted in 5 of the 14 patients from baseline (average FEV1 during the year prior to ivacaftor). On average, FEV1 increased significantly by 5.2 ± 5.6%predicted (p < 0.01). The relative improvement in FEV1 was 19.7 ± 22.1%.ConclusionIvacaftor was effective in many patients with poor lung function. The response was, however, variable. Although the drug appeared safe for most of these patients, increased bronchial secretions may warrant intensified physiotherapy and intravenous antibiotic treatment when ivacaftor is initiated. 相似文献